Skip to main content
OpenTrials
Completed

NCT Number: NCT01802606

Factors Related to Infection Prevention After Tension-free Inguinal Hernia Repair

The investigators conducted the study in 4 teaching hospitals and 2 non-teaching hospitals of Shaanxi Province. Surgeons, clinical pharmacists and nurses took part in patient collection, information registration, protocol performance.

The investigators recruited 1200 patients with inguinal hernia undergoing inguinal hernioplasty in the six hospitals from January 2010 to July 2011. The patients were randomly allocated into control group, cefazolin group and levofloxacin group, with digital meter method , 400 in each group. The data such as age, sex, case number, length of hospital stay, antibiotic usage, post-operative infection, infection site, bacterial culture were filled in self-designed forms on computer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

16 year–18 year

Sex eligibility

All sexes

Study type

Observational

About this study

All of the patients received tension-free inguinal hernia repair with a mesh plug. The surgical-site infection (SSI) was diagnosed according to the criteria of the Centers for Disease Control and Prevention [5-6].

We chose cefazolin sodium and levofloxacin sodium chloride injection as peri-operative antibiotics. Cefazolin sodium is an effective antibiotic with a short plasma elimination half-life against gram-positive cocci (GPC) except for enterococci and meticillin-resistant staphylococci. It is recommended as one of the prior antibacterial agents used for clearing cuts and preventing infection in many countries including China. Levofloxacin sodium chloride injection has a wide anti-bacterial spectrum composed of gram-negative bacteria and gram-positive anaerobic bacteria including anaerobic bacteria. It can remain a high concentration in urine, so it is recommended as an attractive antibiotic for urinary tract operation [5].

In the control group, we gave normal saline as placebo by intravenous drip infusion for 30-60 min before operation. Cefazolin group and levofloxacin group received intravenous administration of cefazolin sodium 1000 mg and levofloxacin sodium chloride injection 200 mg, respectively, for 30-60 min before operation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • males or females aged 16-18 years old;
  • no infection or hematological system disease before surgery;
  • normal liver and kidney function;
  • no pre-operative valvular heart disease;
  • Body mass index (BMI) within 18-32.

Exclusion criteria

  • fail to meet one of the inclusion criteria above;
  • malignant tumor;
  • history of immune system diseases;
  • using or had used corticosteroids or immunosuppressants less than 1 month before surgery;
  • using or had used antibiotics less than 3 d before surgery;
  • pregnancy or lactation.

Treatment and study plan

Primary outcomes

  1. Factors related to infection prevention after tension-free inguinal hernia repair

    Time frame: up to 5 weeks

Secondary outcomes

  1. to offer some evidence pertaining to the factors influencing the prevention of infection and complications after tension-free inguinal hernia repair.

    Time frame: up to 6 months

    Our study aims to offer some evidence pertaining to the factors influencing the prevention of infection and complications after tension-free inguinal hernia repair.

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Registry information

Official study title

Department of Pharmacy, Xijing Hospital

Acronym: infection

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Mar 1, 2013
Registry last updated
Mar 1, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.